Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2022-07-19

Clinical Trial Update: Patients Receiving Induction With Liposomal Daunorubicin and Cytarabine (CPX-351) for Acute Myeloid Leukemia [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update for CPX-351 (liposomal daunorubicin and cytarabine) in acute myeloid leukemia; study terminated with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CPX-351 (liposomal daunorubicin/cytarabine)

Snippet

Sponsor: Medical College of Wisconsin | Conditions: Leukemia, Myeloid, Acute | Phase 4 | Status: TERMINATED | Results posted: 2022-07-19